aod9604 phase 2 trial weight loss results Among participants 4 to 66 years of age with acquired hypothalamic obesity, setmelanotide, a melanocortin-4 receptor agonist, led to significantly greater reductions in body-mass index and hunger than placebo at 52 weeks 5-Amino-1MQ: Block the Fat Size:1000 mcg/ml - 10 ml x 3 AHK-Cu peptide
Pay in 4 interest-free payments of $5.72 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Oct 26 - Oct 31